Session » Antiphospholipid Syndrome Poster

Date: Sunday, October 21, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 156

Assessing the Role of Ascvd Score in Primary Thrombosis Prophylaxis Strategy Among Asymptomatic Antiphospholipid Antibody Carriers

9:00AM-11:00AM: Abstract Number: 165

Clinical and Immunological Features of Antiphospholipid Syndrome in the Elderly: A Retrospective National Multicenter Study

9:00AM-11:00AM: Abstract Number: 161

Clinical and Laboratory Characteristics of Persistently Antiphospholipid Antibody Positive Patients: Retrospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)

9:00AM-11:00AM: Abstract Number: 163

Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase II Item Reduction Survey

9:00AM-11:00AM: Abstract Number: 171

Flow Cytometric Assessment of the Mammalian Target of Rapamycin Pathway Using Antiphospholipid Syndrome As a Disease Model

9:00AM-11:00AM: Abstract Number: 157

Identifying Additional Risk Factors Associated with Thrombosis and Pregnancy Morbidity in a Unique Cohort of Antiphospholipid Antibody Positive Chinese Patients

9:00AM-11:00AM: Abstract Number: 168

IgG Anti-High-Density Lipoproteins Antibodies Discriminate between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients

9:00AM-11:00AM: Abstract Number: 158

Incidence and Prevalence of Antiphospholipid Syndrome in a Health Management Organization (HMO): A 15-Year Study

9:00AM-11:00AM: Abstract Number: 162

Mammalian Target of Rapamycin (mTOR) Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo Reticularis/racemosa

9:00AM-11:00AM: Abstract Number: 170

Predictive Value of Antiphospholipid Antibodies in the Acute Phase of Deep Vein Thrombosis

9:00AM-11:00AM: Abstract Number: 160

Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)

9:00AM-11:00AM: Abstract Number: 169

Prognosis of Patients with Antiphospholipid Syndrome Nephropathy

9:00AM-11:00AM: Abstract Number: 167

Recurrent Thrombosis in Patients with Antiphospholipid Antibodies Following an Initial Venous or Arterial Thromboembolic Event

9:00AM-11:00AM: Abstract Number: 164

Reliability of Lupus Anticoagulant and Anti-Phosphatidylserine/Prothrombin Autoantibodies in Antiphosphospholipid Syndrome: A Multicenter Study

9:00AM-11:00AM: Abstract Number: 174

Rivaroxaban Versus Warfarin As Secondary Thromboprophylaxis in Patients with Antiphospholipid Syndrome: A Randomized, Multicenter, Open-Label, Clinical Trial

9:00AM-11:00AM: Abstract Number: 172

Serum Chemokines and miRNA Levels and Its Association with Cumulative Organ Damage in Patients with Antiphospholipid Syndrome: A Bench to Bedside Study

9:00AM-11:00AM: Abstract Number: 166

Superior Sensitivity for Detection of Primary Antiphospholipid Syndrome By a 9-Test Panel in Patients with Deep Venous Thrombosis, Pulmonary Embolism, and Stroke or Transient Ischemic Attack

9:00AM-11:00AM: Abstract Number: 173

The Efficacy of Treatment with Low Dose Aspirin and Low Molecular Weight Heparin in Pregnant Women with Criteria Anti-Phospholipid Antibodies

9:00AM-11:00AM: Abstract Number: 159

The Frequency of Screening and Prevalence of Antiphospholipid Antibodies in the General Population

« View all sessions from this meeting